Several preclinical studies have shown that pharmacological inhibition of LDHA can suppress glycolytic flux, reduce lactate production, and inhibit pancreatic cancer growth in vitro and in vivo, supporting LDHA and lactate metabolism as potential therapeutic targets rather than established clinical options (60). Here, LDHA is linked to familial pancreatic carcinoma.